The development of COVID-19 treatment

被引:118
|
作者
Yuan, Yongliang [1 ]
Jiao, Baihai [2 ]
Qu, Lili [3 ]
Yang, Duomeng [3 ]
Liu, Ruijuan [1 ]
机构
[1] Zhengzhou Univ, Dept Pharm, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China
[2] Univ Connecticut, Sch Med, Dept Med, Div Nephrol,Hlth Ctr, Farmington, CT USA
[3] Univ Connecticut, Sch Med, Dept Immunol, Hlth Ctr, Farmington, CT 06269 USA
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
基金
中国国家自然科学基金;
关键词
COVID-19; treatments; antiviral agents; neutralizing antibody therapy; Janus kinase inhibitors; JAK-STAT PATHWAY; OPEN-LABEL; CARDIOVASCULAR-DISEASE; RHEUMATOID-ARTHRITIS; RUXOLITINIB; STANDARD; MULTICENTER; FAVIPIRAVIR; TOFACITINIB; COMBINATION;
D O I
10.3389/fimmu.2023.1125246
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest worldwide public health threat of this century. Recent studies have unraveled numerous mysteries of SARS-CoV-2 pathogenesis and thus largely improved the studies of COVID-19 vaccines and therapeutic strategies. However, important questions remain regarding its therapy. In this review, the recent research advances on COVID-19 mechanism are quickly summarized. We mainly discuss current therapy strategies for COVID-19, with an emphasis on antiviral agents, neutralizing antibody therapies, Janus kinase inhibitors, and steroids. When necessary, specific mechanisms and the history of therapy are present, and representative strategies are described in detail. Finally, we discuss key outstanding questions regarding future directions of the development of COVID-19 treatment.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Rivaroxaban in Outpatients with Mild or Moderate COVID-19: Rationale and Design of the Study CARE (CARE-Coalition COVID-19 Brazil VIII)
    Oliveira, Gustavo B. F.
    Neves, Precil Diego M. M.
    Oliveira, Haliton A.
    Catarino, Daniela Ghidetti Mangas
    Alves, Lucas B. O.
    Cavalcanti, Alexandre B.
    Rosa, Regis G.
    Veiga, Viviane C.
    Azevedo, Luciano C. P.
    Berwanger, Otavio
    Lopes, Renato D.
    Avezum, Alvaro
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2023, 120 (03)
  • [32] Nanomaterials as a Versatile Tool for COVID-19 Treatment
    Zeinali, Safieh
    Moafian, Zeinab
    Arshad, Rabia
    Karimi, Fateme
    Zeinalilathori, Somayeh
    Rahdar, Abbas
    Fathi-karkan, Sonia
    Pandey, Sadanand
    BIONANOSCIENCE, 2024, 14 (04) : 3950 - 3987
  • [33] Use of Pharmaceutical Nanotechnology in Treatment of Covid-19: A Systematic Review Study
    Aboulfathiyarmohammadyar, Zahra
    JOURNAL OF PHARMACEUTICAL NEGATIVE RESULTS, 2022, 13 : 184 - 192
  • [34] ESCMID COVID-19 living guidelines: drug treatment and clinical management
    Bartoletti, Michele
    Azap, Ozlem
    Barac, Aleksandra
    Bussini, Linda
    Ergonul, Onder
    Krause, Robert
    Ramon Pano-Pardo, Jose
    Power, Nicholas R.
    Sibani, Marcella
    Szabo, Balint Gergely
    Tsiodras, Sotirios
    Verweij, Paul E.
    Zollner-Schwetz, Ines
    Rodriguez-Bano, Jesus
    CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (02) : 222 - 238
  • [35] Extracorporeal Immunomodulation Treatment and Clinical Outcomes in ICU COVID-19 Patients
    Yessayan, Lenar T.
    Neyra, Javier A.
    Westover, Angela J.
    Szamosfalvi, Balazs
    Humes, H. David
    CRITICAL CARE EXPLORATIONS, 2022, 4 (05) : E0694
  • [36] COVID-19: An Update on Epidemiology, Prevention and Treatment, September-2023
    Simsek-Yavuz, Serap
    INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY, 2023, 5 (03): : 165 - 187
  • [37] Management of hepatitis B virus reactivation due to treatment of COVID-19
    Yip, Terry Cheuk-Fung
    Gill, Madeleine
    Wong, Grace Lai-Hung
    Liu, Ken
    HEPATOLOGY INTERNATIONAL, 2022, 16 (02) : 257 - 268
  • [38] Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment
    Taibe, Noha Samir
    Kord, Maimona A.
    Badawy, Mohamed Ahmed
    Shytaj, Iart Luca
    Elhefnawi, Mahmoud M.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16
  • [39] The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
    Bagca, Bakiye Goker
    Avci, Cigir Biray
    CYTOKINE & GROWTH FACTOR REVIEWS, 2020, 54 : 51 - 61
  • [40] Treatment of Acute COVID-19 and COVID-19 Exposures in Children and Adolescents
    Daniels, Danielle
    Conners, Gregory P.
    PEDIATRIC EMERGENCY CARE, 2024, 40 (03) : 223 - 230